ASSOCIATION OF POLYMORPHIC MARKERS OF TP53 AND MDM2 GENES WITH BREAST CANCER IN FEMALES OF MOSCOW REGION
https://doi.org/10.1234/XXXX-XXXX-2013-2-28-31
Abstract
An association of polymorphic markers Arg72Pro of TP53 gene and T309G of MDM2 gene with risk of breast cancer in females of Moscow region has been studied. We found an association of Pro/Pro genotype of polymorphic marker Arg72Pro with breast cancer development (OR=1.41, p=1x10~5) and with ductal and lobular breast cancer development(OR=1.33, p=0.0001, OR=1.68, p=0.006, respectively). In case of combined susceptible genotype Pro/Pro + TGof TP53 and MDM2 genes we have found highly reliable association with breast cancer and its most frequent subtype — ductal breast carcinoma (p=0.05; p=0.05, respectively).
About the Authors
A. M. Burdennyy
Emanuel Institute of Biochemi cal Physi cs of Russian Academy of Sciences
Russian Federation
Russian Federation
T. P. Kazubskaya
Blokhin Russian Oncological Research Center of Russian Academy of Med ical Sciences, Russia, Moscow
Russian Federation
Russian Federation
E. A. Braga
National Research Center of Russian Federation «GosNII genetika»
Russian Federation
Russian Federation
V. V. Nosikov
Emanuel Institute of Biochemi cal Physi cs of Russian Academy of Sciences; National Research Center of Russian Federation «GosNII genetika»
Russian Federation
Russian Federation
V. I. Loginov
National Research Center of Russian Federation «GosNII genetika»
Russian Federation
Russian Federation
References
1. Блохин Д.Ю. «Посттеномный взгляд» на проблемы онкогенеза // Клиническая онкогематология. Фундаментальные исследования и клиническая практика. — 2009. — Т. 2, №3. — С. 277—282.
2. Желтухин А.О., Чумаков П.М. Повседневные и индуцируемые функции гена р53 // Успехи биоорганической химии. — 2010. — Т. 50. — С. 447—516.
3. Жуков Н.В, Тюляндин С.А, Болотина Л.В., Бяхов М.Ю., Злокачественные опухоли // Journal of malignant tumours. — 2012. — Vol. 2, №2. — P. 168.
4. Имянитов Е.Н. Наследственный рак молочной железы // Практическая онкология. — 2010. — Т. 11, №4. — С. 258—266.
5. Кулигина Е.Ш Эпидемиологические и молекулярные аспекты рака молочной железы // Практическая онкология. — 2010. — Т. 11, №4. — P. 203—216.
6. Силков АН., Горева Е.П., Жовмер А.С., Киреев Ф.Д., Максимов В.Н., Пилипенко И.В., Малиновская Е.А., Бабышкина Н.Н., Литвяков Н.В., Сенников С.В., Козлов ВА Полиморфизм генов ИЛ-18 и ИЛ-1Р у больных раком молочной железы // Российский журнал иммунологии. — 2009. — Т. 3, №12. — С. 259—266.
7. Чиссова В.И., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2010 году (заболеваемость и смертность). — М.: ФГБУ «МНИОИ им. П.А. Герцена» Мин-здравсоцразвития России, 2012. — 260 с.
8. Alvarez R.H., Valero V., Hortobagyi G.N. Emerging Targeted Therapies for Breast Cancer // Journal of clinical oncology. — 2010. — Vol. 28, №20. — P. 3366—3379.
9. Ayoub N., Lucas C., Kaddoumi A. Genomics and pharmaco-genomics of breast cancer: current knowledge and trends // Asian Pac. J. Cancer Prev. — 2011. — Vol. 12, №5. — P. 1127—1140.
10. Bonafе M., Salvioli S., Barbi C., Trapassi C., Tocco F., Storci G., Invidia L., Vannini I., Rossi M., Marzi E., Mishto M., Capri M., Olivieri F., Antonicelti R., Memo M., Uberti D., Nacmias B., Sorbi S., Monti D., Franceschi C. The different apoptotic potential of the p53 codon 72 alleles increases with age and modulates in vivo ischaemia-induced cell death // Cell Death Difer. — 2004. — Vol. 11, №9. — P. 962—973.
11. Bond G.L., Hirshfield K.M., Kirchhof T., Alexe G., Bond E.E., Robins H., Bartel F., Taubert H., Wuerl P., Hait W., Toppmeyer D., Offit K., Levine A.J. MDM2 T309G accelerates tumor formation in a gender-specific and hormone-dependent manner // Cancer Res. — 2006. — Vol. 66, №10. — P. 5104—5110.
12. Faghani M., Ghasemi F.M., Nikhbakht M., Salehi M. TP53 PIN3 polymorphism associated with breast cancer risk in Iranian women // Indian J. Cancer. — 2011. — Vol. 48, №3. — P. 298—302.
13. Leeuwen F.E., Van’t Veer L.J., Pharoah P.D.P., Easton D.F., Shah M., Humphreys M., Dоеrk T., Reincke S.A., Fager-holm R., Blomqvist C., Nevanlinna H. Combined effects of single nucleotide polymorphisms TP53 R72P and MDM2 T309G, and p53 expression on survival of breast cancer patients // Breast Cancer Res. — 2009. — Vol. 11, №6. — R89.
14. Meindl A., Ditsch N., Kast K., Rhiem K., Schmutzler R.K. Hereditary breast and ovarian cancer: new genes, new treatments, new concepts // Dtsch. Arztebl. Int. — 2011. — Vol. 108 №19. — P. 323—330.
15. Orsted D.D., Bojesen S.E., Tybjaerg-Hansen A., Nordestga-ard B.G. Tumor suppressor p53 Arg72Pro polymorphism and longevity, cancer survival, and risk of cancer in the general population // J. Exp. Med. — 2007. — Vol. 204, №6. — P. 1295—1301.
16. Petenkaya A., Bozkurt B., Akilli-Ozturk O., Kaya H.S., Gur-Dedeoglu B., Yulug I.G. Lack of association between the MDM2- T309G polymorphism and breast cancer risk // Anticancer Res. — 2006. — Vol. 26, №6C. — P. 4975-4977.
17. Peterson C. Drug therapy of cancer // Eur. J. Clin. Pharmacol. — 2011. — Vol. 67, №5. — P. 437—447.
18. Proestling K., Hebar A., Pruckner N., Marton E., Vinat-zer U., Schreiber M. The Pro Allele of the p53 Codon 72 Polymorphism Is Associated with Decreased Intratumoral Expression of BAX and p21, and Increased Breast Cancer Risk // PLoS One. — 2012. — Vol. 7, №10. — e47325.
19. Reinholz M.M., Bruzek A.K., Visscher D.W., Lingle W.L., Schroeder M.J., Perez E.A., Jenkins R.B. Breast cancer and aneuso-my 17: implications for carcinogenesis and therapeutic response // Lancet Oncol. — 2009. — Vol. 10, №3. — P. 267—277.
20. Rodier F., Campisi J., Bhaumik D. Two faces of p53: aging and tumor suppression // Nucletc Acids Res. — 2007. — Vol. 35, №22. — P. 7475—7484.
21. Tenhagen M., van Diest P.J., Ivanova I.A., van der Wall E., van der Groep P. Fibroblast growth factor receptors in breast cancer: expression, downstream effects, and possible drug targets // Endocr. Relat. Cancer. — 2012. — Vol. 19, №4. — P. 115—129.
22. Tian Y., Hou Y., Zhou X., Cheng H., Zhou R. Tumor Suppressor RASSF1A Promoter: p53 Binding and Methylation // PLoS ONE — 2011. — Vol. 6, №2. — e17017.
23. Tommiska J., Eerola H., Hetnonen M., Salonen L., Kaa-re M., Tallila J., Ristimaki A., von Smitten K., Aittomaki K., Heik-kila P., Blomqvist C., Nevanlinna H. MDM2 T309G accelerates breast and ovarian carcinogenesis in BRCA1 and BRCA2 carriers of Jewish-Ashkenazi descent // Clin. Cancer Res. — 2005. — Vol. 11, №14. — P. 5098—5103.
24. van Heemst D., Mooij aart S.P., Beekman M., Schreuder J., de Craen A.J., Brandt B.W., Slagboom P.E., Westendorp R.G. Variation in the human TP53 gene affects old age survival and cancer mortality // Exp. Gerontol. — 2005. — Vol. 40, №1—2. — P. 11—15.
25. Whibley C., Pharoah P.D., Hollstein M. p53 polymorphisms: cancer implications // Nat. Rev. Cancer. — 2009. — Vol. 9, №2. — P. 95—107.
26. Yarden R.I., Friedman E., Metsuyanim S., Olender T., Ben-As-her E., Papa M.Z. MDM2 T309G accelerates breast and ovarian carcinogenesis in BRCA1 and BRCA2 carriers of Jewish-Ashkenazi descent // Breast Cancer Res. Treat. — 2008. — Vol. 111, №3. — P. 497—504.
Review
For citations:
Burdennyy A.M., Kazubskaya T.P., Braga E.A., Nosikov V.V., Loginov V.I. ASSOCIATION OF POLYMORPHIC MARKERS OF TP53 AND MDM2 GENES WITH BREAST CANCER IN FEMALES OF MOSCOW REGION. Medical Genetics. 2013;12(2):28-31. (In Russ.) https://doi.org/10.1234/XXXX-XXXX-2013-2-28-31
Views:
813
Email this article 